Herpich F, Rincon F et al (2020) Management of acute ischemic stroke. Crit Care Med 48(11):1654–1663. https://doi.org/10.1097/CCM.0000000000004597

Article  PubMed  PubMed Central  Google Scholar 

Sun YF, Zhang Q, Li JM et al (2015) Progress in the treatment of acute ischemic stroke by intravenous thrombolysis. J Chin Gen Pract 18:1371–1375

Google Scholar 

Berge E, Whiteley W, Audebert H et al (2021) European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J 6(1):I–LXII. https://doi.org/10.1177/2396987321989865

Article  PubMed  PubMed Central  Google Scholar 

Steven JW, Adrienne ND, Truman JM et al (2020) Tenecteplase Thrombolysis for Acute Ischemic Stroke. Stroke 51(11):3440–3451. https://doi.org/10.1161/STROKEAHA.120.029749

Article  Google Scholar 

Mark WP, Vignan Y, Leonid C et al (2024) Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial. Lancet Neurol 23(8):775–786. https://doi.org/10.1016/S1474-4422(24)00206-0

Article  Google Scholar 

Campbell BCV, Mitchell PJ, Churilov L et al (2018) Tenecteplase versus alteplase before endovascular thrombectomy (EXTEND-IA TNK): A multicenter, randomized, controlled study. Int J Stroke 13(3):328–334. https://doi.org/10.1177/1747493017733935

Article  PubMed  Google Scholar 

Bala F, Singh N, Buck B et al (2023) Safety and efficacy of tenecteplase compared with alteplase in patients with large vessel occlusion stroke a prespecified secondary analysis of the ACT randomized clinical trial. JAMA Neurol 80(8):824–832. https://doi.org/10.1001/jamaneurol.2023.2094

Article  PubMed  PubMed Central  Google Scholar 

Xuya H, Bharath KC, Suzanne ML et al (2015) Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol 14(4):368–376. https://doi.org/10.1016/S1474-4422(15)70017-7

Article  Google Scholar 

Bijoy KM, Bk BH, Nishita S et al (2022) Intravenous tenecteplase compared with alteplase for acuteischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet 400(10347):161–169. https://doi.org/10.1016/S0140-6736(22)01054-6

Article  Google Scholar 

Zhang Xu, Wan T-F, Chen J et al (2023) Tenecteplase versus alteplase for patients with acute ischemic stroke: a meta-analysis of randomized controlled trials. Aging 15(24):14889–14899. https://doi.org/10.18632/aging.205315

Article  PubMed  PubMed Central  Google Scholar 

Palaiodimou L, Katsanos AH, Turc G et al (2024) Tenecteplase vs alteplase in acute ischemic stroke within 4.5 hours: a systematic review and meta-analysis of randomized trials. Neurology 103(9):e209903. https://doi.org/10.1212/WNL.0000000000209903

Article  PubMed  Google Scholar 

Katsanos AH, Safouris A, Sarraj A et al (2021) Intravenous thrombolysis with tenecteplase in patients with large vessel occlusions: systematic review and meta-analysis. Strok. 52(1):308–312. https://doi.org/10.1161/STROKEAHA.120.030220

Article  Google Scholar 

The EZ, Lin NN, Matar M et al (2023) Different dosing regimens of Tenecteplase in acute ischemic stroke: A network meta-analysis of the clinical evidence. Eur Stroke J. 8(1):93–105. https://doi.org/10.1177/23969873221129924

Article  PubMed  Google Scholar 

Keith WM, Gary AF, Ian F et al (2024) Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial. Lancet Neurol 23(11):1087–1096. https://doi.org/10.1016/S1474-4422(24)00377-6

Article  Google Scholar 

Nicola L, Vojtech N, Jörg A et al (2017) Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol 16(10):781–788. https://doi.org/10.1016/S1474-4422(17)30253-3

Article  Google Scholar 

Christopher EK, Halvor N, Bernt HH et al (2022) Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Lancet Neurol 21(6):511–519. https://doi.org/10.1016/S1474-4422(22)00124-7

Article  Google Scholar 

Shuya L, Yuesong P, Ziran W et al (2022) Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study. Stroke Vasc Neurol 7(1):47–53. https://doi.org/10.1136/svn-2021-000978

Article  Google Scholar 

Yongjun W, Shuya L, Yuesong P et al (2023) Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet 401(10377):645–654. https://doi.org/10.1016/S0140-6736(22)02600-9

Article  Google Scholar 

Mark P, Neil S, Andrew B et al (2012) A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 366(12):1099–1107. https://doi.org/10.1056/NEJMoa1109842

Article  Google Scholar 

Clarke Haley E, J, John L P Thompson, James C Grotta, et al (2010) Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 41(4):707–711. https://doi.org/10.1161/STROKEAHA.109.572040

Article  PubMed  PubMed Central  Google Scholar 

Tanswell P, Modi N, Combs D et al (2002) Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 41(15):1229–1245. https://doi.org/10.2165/00003088-200241150-00001

Article  PubMed  Google Scholar 

Wang X, Tsuji K, Lee SR et al (2004) Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 35(11 Suppl 1):2726–2730. https://doi.org/10.1161/01.STR.0000143219.16695

Article  PubMed  Google Scholar 

Campbell BCV, Mitchell PJ, Churilov L et al (2018) Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med 378(17):1573–1582. https://doi.org/10.1056/NEJMoa1716405

Article  PubMed  Google Scholar 

Huang J, Zheng H, Zhu X et al (2024) Tenecteplase versus alteplase for the treatment of acute ischemic stroke: a meta-analysis of randomized controlled trials. Ann Med 56(1):2320285. https://doi.org/10.1080/07853890.2024.2320285

Article  PubMed  PubMed Central  Google Scholar 

Rose D, Cavalier A, Kam W et al (2023) Complications of intravenous tenecteplase versus alteplase for the treatment of acute ischemic stroke: a systematic review and meta-analysis. Stroke 54(5):1192–1204

Article  PubMed  PubMed Central  Google Scholar 

Palaiodimou L, Katsanos AH, Turc G et al (2024) Tenecteplase vs alteplase in acute ischemic stroke within 4.5 hours. Neurology. https://doi.org/10.1212/WNL.0000000000209903

Article  PubMed  Google Scholar 

Tsivgoulis G, Katsanos AH, Schellinger PD et al (2023) Advanced neuroimaging in acute ischemic stroke: from triage to prognostication. Stroke 54(2):567–577. https://doi.org/10.1016/j.neurad.2014.11.003

Article  Google Scholar 

Wahlgren N, Ahmed N, Dávalos A et al (2007) Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study. Lancet 369(9558):275–282. https://doi.org/10.1016/S0140-6736(07)60149-4

Article  PubMed  Google Scholar